Knowing from Wang et al. [38] that SLC22A5 expression is much higher in ER positive breast cancer than in ER negative one, also confirmed by Lu et al. [106], we further restricted this analysis to differentiate survival prognoses across ER+ and ER− patients (Figure 4E, 4F). This evidence concerns the gene ESR1 and breast carcinoma.